Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: **NEW ASSIGNMENT** NATURE OF CONVEYANCE: SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date	
Dyax Corp., a Delaware Corporation	08/05/2008	

RECEIVING PARTY DATA

Name:	owen Healthcare Royalty Partners, L.P.					
Street Address:	177 Broad Street					
Internal Address:	Suite1101					
City:	Stamford					
State/Country:	CONNECTICUT					
Postal Code:	06901					

PROPERTY NUMBERS Total: 31

Property Type	Number
Patent Number:	5223409
Patent Number:	5403484
Patent Number:	5571698
Patent Number:	5837500
Patent Number:	6979538
Patent Number:	7208293
Patent Number:	7118879
Patent Number:	7244592
Application Number:	07240160
Application Number:	10207797
Application Number:	10414643
Application Number:	11745199
Application Number:	11763251
Application Number:	60362403
	DATENT

PATENT

I.	
Application Number:	10026925
Application Number:	11416460
Application Number:	60256380
Application Number:	09988899
Application Number:	11862791
Application Number:	09837306
Application Number:	10000516
Application Number:	10045674
Application Number:	11365556
Application Number:	60198069
PCT Number:	US8903731
PCT Number:	US9201456
PCT Number:	US9201539
PCT Number:	US0013682
PCT Number:	US0150297
PCT Number:	US0112454
PCT Number:	US0212405

CORRESPONDENCE DATA

Fax Number: (202)408-3141

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 800-927-9801 x2348
Email: jpaterso@cscinfo.com

Correspondent Name: Corporation Service Company

Address Line 1: 1090 Vermont Avenue NW, Suite 430

Address Line 2: Attn: Jean Paterson

Address Line 4: Washington, DISTRICT OF COLUMBIA 20005

ATTORNEY DOCKET NUMBER:	676805
NAME OF SUBMITTER:	Jean Paterson

Total Attachments: 13

source=8-6-08 Dyax-PAT#page1.tif

source=8-6-08 Dyax-PAT#page2.tif

source=8-6-08 Dyax-PAT#page3.tif

source=8-6-08 Dyax-PAT#page4.tif

source=8-6-08 Dyax-PAT#page5.tif

source=8-6-08 Dyax-PAT#page6.tif

source=8-6-08 Dyax-PAT#page7.tif

source=8-6-08 Dyax-PAT#page8.tif

source=8-6-08 Dyax-PAT#page9.tif

source=8-6-08 Dyax-PAT#page10.tif source=8-6-08 Dyax-PAT#page11.tif source=8-6-08 Dyax-PAT#page12.tif source=8-6-08 Dyax-PAT#page13.tif

EXECUTION VERSION

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this "Patent Security Agreement") is made and entered into as of August 5, 2008 (the "Effective Date") by and between Dyax Corp., a Delaware corporation (including its successors and assigns, "Grantor"), and Cowen Healthcare Royalty Partners, L.P., a Delaware limited partnership (including its successors and assigns, "Grantee").

WITNESSETH:

WHEREAS, Grantor and Grantee are parties to that certain Security Agreement, dated of even date herewith (as amended, supplemented and otherwise modified from time to time, the "Security Agreement");

WHEREAS, pursuant to the Security Agreement, Grantor is required to execute and deliver to Grantee this Patent Security Agreement for the purposes of filing;

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

- 1. **DEFINED TERMS.** All capitalized terms used but not otherwise defined herein have the meanings given to them in the Security Agreement.
- 2. **GRANT OF SECURITY INTEREST IN PATENT COLLATERAL.** Grantor hereby grants to Grantee a continuing first priority security interest in all of such Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Patent Collateral"):
 - (a) all of the patents and patent applications set forth on Schedule I hereto;
 - (b) all issued patents, reissues, reexaminations, renewals, and extensions of the foregoing and any continuations, continuations-in-part or divisionals of the foregoing;
 - (c) all rights to sue for past, present and future infringement of any such patent right, including the right to receive all income, royalties and damages therefrom; and
 - (d) to the extent not otherwise included, all products and proceeds of the foregoing.
- 3. <u>SECURITY FOR OBLIGATIONS</u>. This Patent Security Agreement and the security interest created hereby secures the payment and performance of all the Secured Obligations, whether now existing or arising hereafter.

- 4. <u>SECURITY AGREEMENT</u>. The security interests granted pursuant to this Patent Security Agreement are granted in conjunction with the security interests granted to Grantee pursuant to the Security Agreement. Grantor hereby acknowledges and affirms that the rights and remedies of Grantee with respect to the security interest in the Patent Collateral set forth herein are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.
- 5. <u>AUTHORIZATION TO SUPPLEMENT</u>. Grantor shall give Grantee notice in accordance with the Security Agreement of any additional patents or applications therefor after the date hereof that are included in the Collateral. Grantor hereby authorizes Grantee unilaterally to modify this Agreement by amending <u>Schedule I</u> to include any such future patents or applications therefor of Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend <u>Schedule I</u> shall in any way affect, invalidate or detract from Grantee's continuing security interest in all Collateral, whether or not listed on <u>Schedule I</u>.
- 6. **GOVERNING LAW.** This Agreement shall be governed by, and construed, interpreted and enforced in accordance with, the laws of the State of New York, without giving effect to the principles of conflicts of law thereof.
- 7. <u>COUNTERPARTS: EFFECTIVENESS</u>. This Agreement may be executed in two or more counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto.

IN WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be duly executed by their respective authorized officers as of the date first above written.

GRANTOR:

Name: Ivana Magovrevic-Liebisch, PhD, JD
Title: Executive Vice President, Admin.

and General Counsel

GRANTEE:

COWEN HEALTHCARE ROYALTY PARTNERS, L.P.,

Cowen Healthcare Royalty GP, LLC,

its General Partner

By:

Name: Gregory B. Brown, M.D. Title: Managing Director

Patent Security Agreement

PATENT

1N WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be duly executed by their respective authorized officers as of the date first above written.

GRANTOR:

DYAX CORP.

Name: Ivana Magovcevic-Liebisch, PhD, JD Title: Executive Vice President, Admin.

and General Counsel

GRANTEE:

COWEN HEALTHCARE ROYALTY PARTNERS, L.P.,

Cowen Healthcare Royalty GP, LLC, its General Portner By:

By:

Name Gregory B. Brown, M.D.

Title: Managing Director

Patent Security Agreement

SCHEDULE I TO PATENT SECURITY AGREEMENT

PATENTS

LFRP Patents

DYAX (OWNER) PHAGE DISPLAY PATENT RIGHTS

	DYAX PHAGE DISPLAY PATENT RIGHTS									
M ATTER	SERIAL	PATENT	PUBL	TITLE	STATUS	ISSUE	EXPIRATION			
Ladner 1	07/240,160			GENERATION AND SELECTION OF NOVEL DNA- BINDING PROTEINS AND POLYPEPTIDES	ABANDONED		7 /15/1991			
Ladner 1 CA	610176	1340288		GENERATION AND SELECTION OF NOVEL DNA- BINDING PROTEINS AND POLYPEPTIDES	ISSUED	12/29/1998	12/29/2015			
Ladner 1 Div 1 EP	96112867.5	0768377	EP0768377	GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS	ABANDONED	4 /16/1997	1 /17/2005			
Ladner 1 Div 2 EP	00106289.2		EP1026240	GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS	ABANDONED		1 /18/2006			
Ladner 1 Div 3 EP	05000796.2		EP1541682	GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS	ABANDONED		7 /31/2008			
Ladner I Div 4 EP	07122683.1			GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS	PENDING		9 /1 /2009			
Ladner 1 EP	89910702.3	0436597	EP0436597	GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS	REVOKED	4 /2 /1997	7 /2 /2002			
Ladner 1 IE	2834/89			GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS	PUBLISHED		9 /1 /2009			
Ladner l IL	91501	91501		GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS	ISSUED	6 /11/1998	9 /1 /2009			
Ladner 1 JP	510087/1989	3771253		GENERATION AND	ISSUED	2 /17/2006	9 /1 /2009			

		DYA	X PHAGE DIS	PLAY PATENT RIG	HTS		
M ATTER	SERIAL	PATENT	PUBL	TITLE	STATUS	ISSUE	EXPIRATION
				SELECTION OF RECOMBINANT VARIED BINDING PROTEINS			
Ladner 1 PCT	PCT/US89/03731		WO9002809	GENERATION AND SELECTION OF RECOMBINANT VARIED BINDING PROTEINS	PUBLISHED		
Ladner 1.1 IL	120941	120941	120941	CHIMERIC BINDING PROTEIN	ISSUED	9 /20/2005	9 /1 /2009
Ladner 1.2 IL	120940	120940		FUSION PROTEINS DISPLAYED DISPLAYABLE ON THE SURFACE OF FILAMENTOUS PHAGE AND A RECOMBINANT FILAMENTOUS PHAGE BEARING SAME	ISSUED	9 /20/2005	9 /1 /2009
Ladner 1.3 IL	120939	120939		METHOD FOR OBTAINING NUCLEIC ACID ENCODING A PROTEINACOUS BINDING DOMAIN	ISSUED	10/25/2001	1 /9 /2009
Ladner 7	07/664,989	5,223,409		DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS	ISSUED	6 /29/1993	6 /29/2010
Ladner 7A CA	2105300			PROCESS FOR THE DEVELOPMENT OF BINDING MINI- PROTEINS	PENDING		2 /27/2012
Ladner 7A Div 1 EP	02015673.3	1279731	1279731	PROCESS FOR THE DEVELOPMENT OF BINDING MINI- PROTEINS	ISSUED	5 /30/2007	2 /27/2012
Ladner 7A Div 2 EP	07010609.1		EP1820858	PROCESS FOR THE DEVELOPMENT OF BINDING MINI- PROTEINS	PUBLISHED		2 /27/2012
Ladner 7A EP	92908057.0		EP0575485	PROCESS FOR THE DEVELOPMENT OF BINDING MINI- PROTEINS	ABANDONED		4 /1 /2003
Ladner 7A JP	507558/1992			PROCESS FOR THE DEVELOPMENT OF BINDING MINI- PROTEINS	ALLOWED		2 /27/2012
Ladner 7A PCT	PCT/US92/01456		WO9215677	PROCESS FOR THE DEVELOPMENT OF BINDING MINI- PROTEINS	PUBLISHED		
Ladner 7B AT	238311/2002	0573611	262036	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012
Ladner 7B BE	130929/2003	0573611	2004-221	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012
Ladner 7B	2105303			DISPLAY PHAGE	ABANDONED		5 /24/2004

	DYAX PHAGE DISPLAY PATENT RIGHTS										
M ATTER	SERIAL	PATENT	PUBL	TITLE	STATUS	ISSUE	EXPIRATION				
CA											
Ladner 7B CH	04006079.0	0573611	1452599	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2 O 04	2 /28/2012				
Ladner 7B DE	92908799.7	69233325.8- 08	DE 69233325T2	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012				
Ladner 7B DK	92908799.7	0573611	0573611	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2 004	2 /28/2012				
Ladner 7B EP	92908799.7	0573611	EP0573611	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2/004	2 /28/2012				
Ladner 7B EP Div 1	04006079.0		1452599	IMPROVED EPITOPE DISPLAYING PHAGE	PUBLISHED		2 /28/2012				
Ladner 7B ES	92908799.7	0573611	0573611	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012				
Ladner 7B FR	92908799.7	69233325.8- 08		IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012				
Ladner 7B GB	92908799.7	0573611	0573611	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012				
Ladner 7B GR	92908799.7	3049248		IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012				
Ladner 7B IT	92908799.7	0573611	0573611	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012				
Ladner 7B JP	508216/1992	3447731		IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	7 /4 /2003	2 /28/2012				
Ladner 7B JP Div 1	92908799.7			IMPROVED EPITOPE DISPLAYING PHAGE	ABANDONED		12/12/2003				
Ladner 7B JP Div 2	130929/2003		2004-221	IMPROVED EPITOPE DISPLAYING PHAGE	PUBLISHED		2 /28/2012				
Ladner 7B LI	92908799.7	0573611	0573611	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004					
Ladner 7B LU	92908799.7	0573611	0573611	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012				
Ladner 7B MC	92908799.7	0573611	0573611	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012				
Ladner 7B NL	92908799.7	0573611	0573611	IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012				
Ladner 7B PCT	PCT/US92/01539		WO9215679	IMPROVED DISPLAY PHAGE	PUBLISHED						
Ladner 7B SE	92908799.7	0573611		IMPROVED EPITOPE DISPLAYING PHAGE	ISSUED	3 /17/2004	2 /28/2012				
Ladner 7D	08/009,319	5,403,484		VIRUSÉS EXPRESSING CHIMERIC BINDING	ISSUED	4 /4 /1995	4 /4 /2012				

	na). I cu cui a macai ca 	DYA	X PHAGE DIS	PLAY PATENT RIG	HTS		
M ATTER	SERIAL	PATENT	PUBL	TITLE	STATUS	ISSUE	EXPIRATION
				PROTEINS			
Ladner 7E	08/057,667	5,571,698		DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS	ISSUED	11/5 /1996	6 /29/2010
Ladner 7F	08/415,922	5,837,500		DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS	ISSUED	11/17/1998	6 /29/2010
Ladner 7J	09/781,988	6,979,538	US20020150881	DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS	ISSUED	12/27/2005	6 /29/2010
Ladner 7M	09/893,878	7,208,293	US20030113717	DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS	ISSUED	4 /24/2007	6 /29/2010
Ladner 70	10/126,544	7,118,879	US20040023205	METHOD OF RECOVERING A NUCLEIC ACID ENCODING A PROTEINACEOUS BINDING DOMAIN WHICH BINDS A TARGET MATERIAL	ISSUED	10/10/2006	6 /29/2010
Ladner 7R	10/207,797		US20060084113	DIRECTED EVOLUTION OF DISULFIDE BONDED MICROPROTEINS	ALLOWED		
Ladner 7S	10/414,643			METHOD OF RECOVERING A NUCLEIC ACID ENCODING A PROTEINACEOUS BINDING DOMAIN WHICH BINDS A TARGET MATERIAL	ABANDONED		10/23/2006
Ladner 7T	11/745,199		2007-0259417	DIRECTED EVOLUTION OF DISULFIDE BONDED PROTEINS	PUBLISHED		

DYAX (OWNER) ANTIBODY TECHNOLOGY PATENTS (cont)

ANTIBODY REFORMATTING PATENTS

MARCHE MARCHES	DYAX ANTIBODY REFORMATTING PATENT RIGHTS										
MATTER	SERIAL	PATENT	PUBL	TITLE	STATUS	ISSUE	EXPIRATION				
042001	10/383,902	7,244,592	US 2003-0224408 A1	LIGAND SCREENING AND DISCOVERY	ISSUED	7 /17/2007	3 /7 /2023				
042002	11/763,251			LIGAND SCREENING AND DISCOVERY	PENDING		3 /7 /2023				
042P01	60/362,403			LIGAND SCREENING AND DISCOVERY	EXPIRED		3 /7 /2003				

PATENT

SYNTHETIC CDR LIBRARIES - LADNER

***************************************	DYAX SYNTHETIC CDR LIBRARY PATENT RIGHTS- LADNER ET AL.										
MATTER	SERIAL	PATENT	PUBL	TITLE	STATUS	ISSUE	EXPIRATI ON				
141001	10/026,925		US 20030119056 A1	FOCUSED LIBRARIES OF GENETIC PACKAGES	ABANDONED		9 /8 /2006				
141002	11/416,460		US-2006-0257937- A1	FOCUSED LIBRARIES OF GENETIC PACKAGES	PUBLISHED		12/18/2021				
141AU1	2002249854		WO02/061071 A2	FOCUSED LIBRARIES OF GENETIC PACKAGES	ALLOWED		12/18/2021				
141AU2	2007214299			FOCUSED LIBRARIES OF GENETIC PACKAGES	PENDING		8 /29/2027				
141CA1	2432377			FOCUSED LIBRARIES OF GENETIC PACKAGES	PENDING		12/18/2021				
141EP1	01998098.6		EP1360288	FOCUSED LIBRARIES OF GENETIC PACKAGES	PUBLISHED		12/18/2021				
141JP1	2002-561628			FOCUSED LIBRARIES OF GENETIC PACKAGES	PENDING		12/18/2021				
141J P 2	2008-99833			FOCUSED LIBRARIES OF GENETIC PACKAGES	PENDING		4 /7 /2028				
141 P 01	60/256,380			FOCUSED LIBRARIES OF GENETIC PACKAGES	ABANDONED		12/18/2001				
[41WO]	PCT/US01/5 0297			FOCUSED LIBRARIES OF GENETIC PACKAGES	PUBLISHED						

DYAX (OWNER) ANTIBODY TECHNOLOGY PATENTS

NOVEL FAB FRAGMENTS - HOOGENBOOM ET AL.

MATTER	SERIAL	PATENT	PUBL	TITLE	STATUS	ISSUE	EXPIRATI ON
139001	09/988,899		US 2002-0102613 A1	NOVEL FAB FRAGMENT LIBRARIES AND METHODS FOR THEIR USE	ABANDONED		10/29/2007
139002	11/862,791		US20080108514	NOVEL FAB FRAGMENT LIBRARIES AND METHODS FOR THEIR USE	PUBLISHED		5 /18/2019
139AU1	51422/00	780145		NOVEL FAB FRAGMENT LIBRARIES AND METHODS FOR THEIR USE	ISSUED	1 /14/2005	5 /18/2019
139CA1	2372582			NOVEL FAB FRAGMENT LIBRARIES AND METHODS FOR THEIR USE	PENDING		5 /18/2019
139EP1	99201558.6		EP1054018	NOVEL FAB FRAGMENT LIBRARIES AND METHODS FOR THEIR USE	PUBLISHED		5 /18/2019
139JP1	2000-618429			NOVEL FAB FRAGMENT LIBRARIES AND METHODS FOR	PUBLISHED		5 /18/2019

MATTER	SERIAL	PATENT	PUBL	TITLE	STATUS	ISSUE	EXPIRATI ON
				THEIR USE			
139WO1	PCT/US00/1 3682		WO00/70023	NOVEL FAB FRAGMENT LIBRARIES AND METHODS FOR THEIR USE	PUBLISHED		

CJ LIBRARY - LADNER ET AL.

	DYAX CJ LIBRARY PATENT RIGHTS - LADNER ET AL.						
MATTER	SERIAL	PATENT	PUBL	TITLE	STATUS	ISSUE	EXPIRATION
140001	09/837,306	AND COLUMN TO SERVICE OF THE SERVICE	US 2004- 0029113 A1	NOVEL METHODS OF CONSTRUCTING LIBRARES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND NOVEL LIBRARIES	ABANDONED		6 /16/2006
140002	10/000,516			NOVEL METHODS OF CONSTRUCTIONG LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES	ABANDONED		2 /22/2002
140003	10/045,674		US 2003- 0232333 AI	NOVEL METHODS OF CONSTRUCTIONG LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES	PUBLISHED		4 /17/2021
140004	11/365,556		US-2006- 0166252-A1	NOVEL METHODS OF CONSTRUCTING LIBRARES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND NOVEL LIBRARIES	PUBLISHED		4 /17/2021
140AUI	2001253589	2001253589		NOVEL METHODS OF CONSTRUCTIONG LIBRARIES OF HUMAN FAB ANTIBODY FRAGMENTS	ISSUED	11/29/2007	4 /17/2021

PATENT

		DYAX CJ	LIBRARY PA	TENT RIGHTS - LAD	NER ET AL.	/cs/ cs/dan/as/assa/d/ Ld/ -s/as/da// /	
MATTER	SERIAL	PATENT	PUBL	TITLE	STATUS	ISSUE	EXPIRATION
				DISPLAYED ON FILAMENTOUS PHAGE (CJ Library)			·
140AU2	2002307422		(WO02083872)	NOVEL METHODS OF CONSTRUCTIONG LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES	PUBLISHED		4 /17/2022
140AU3	2007211861			NOVEL METHODS OF CONSTRUCTIONG LIBRARIES OF HUMAN FAB ANTIBODY FRAGMENTS DISPLAYED ON FILAMENTOUS PHAGE (CJ Library)	PENDING		8 /21/2027
140CA1	2406236		(WO01/79481)	NOVEL METHODS OF CONSTRUCTIONG LIBRARIES OF HUMAN FAB ANTIBODY FRAGMENTS DISPLAYED ON FILAMENTOUS PHAGE	PUBLISHED		4 /17/2021
140CA2	2458462			NOVEL METHODS OF CONSTRUCTIONG LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES	PENDING		4 /17/2022
140EP1	01927108.9		EP1276855	NOVEL METHODS OF CONSTRUCTIONG LIBRARIES OF HUMAN FAB ANTIBODY FRAGMENTS DISPLAYED ON FILAMENTOUS PHAGE	PUBLISHED		4 /17/2021
140EP2	02762148.1		EP1578903	NOVEL METHODS OF CONSTRUCTIONG LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES	PUBLISHED		4 /17/2022
140JP1	2001-577464			NOVEL METHODS OF CONSTRUCTIONG LIBRARIES OF HUMAN FAB ANTIBODY FRAGMENTS DISPLAYED ON	PENDING		4 /17/2021

	DYAX CJ LIBRARY PATENT RIGHTS - LADNER ET AL.								
MATTER	SERIAL	PATENT	PUBL	TITLE	STATUS	ISSUE	EXPIRATION		
				FILAMENTOUS PHAGE					
140.ГР2	PCT/US02/12405			NOVEL METHODS OF CONSTRUCTIONG LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES	PENDING		4 /17/2022		
140P01	60/198,069			NOVEL METHODS OF CONSTRUCTIONG LIBRARIES OF HUMAN FAB ANTIBODY FRAGMENTS DISPLAYED ON FILAMENTOUS PHAGE	ABANDONED		4 /17/2001		
140WO1	PCT/US01/12454		WO 01/79481	NOVEL METHODS OF CONSTRUCTIONG LIBRARIES OF HUMAN FAB ANTIBODY FRAGMENTS DISPLAYED ON FILAMENTOUS PHAGE	PUBLISHED				
140WO2	PCT/US02/12405		WO 02083872	NOVEL METHODS OF CONSTRUCTIONG LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES	PUBLISHED				

RECORDED: 08/08/2008